找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma; Rana R. McKay,Eric A. Singer Book 2023 The Editor(s) (if applic

[復(fù)制鏈接]
樓主: Encomium
31#
發(fā)表于 2025-3-27 00:21:43 | 只看該作者
Subsequent Line Systemic Treatment Options for Advanced Renal Cell Carcinomaof care. Subsequently, the data for treatment options in second line and beyond has evolved. Recent phase 2/3 trials and retrospective analyses provide insights into treatment in the post-immunotherapy setting. It is crucial to compare the different types of treatments available to guide safe and ef
32#
發(fā)表于 2025-3-27 02:22:24 | 只看該作者
33#
發(fā)表于 2025-3-27 06:46:48 | 只看該作者
Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcive radiation therapy (SAbR) at locations that were not previously feasible. While in the era of conventional protracted course radiation, renal cell cancer (RCC) was assessed to be radioresistant, and radiation therapy for RCC was even considered toxic, in the era of ablative hypofractionated radiat
34#
發(fā)表于 2025-3-27 09:28:19 | 只看該作者
Systemic Therapies for Advanced Non-Clear Cell Renal Cell Carcinoma RCC comprises a heterogeneous group of tumors—from the initial description of two subtypes in 1952 (clear cell and granular cell), the classification of kidney cancer has evolved to recognize a large variety of histological subtypes according to the World Health Organization (WHO), and over 50 gene
35#
發(fā)表于 2025-3-27 14:12:20 | 只看該作者
36#
發(fā)表于 2025-3-27 19:55:57 | 只看該作者
37#
發(fā)表于 2025-3-27 22:29:16 | 只看該作者
Predictive Biomarkers in Advanced Renal Cell Carcinomas with advanced renal cell carcinoma. Although many of these biomarkers are not fully validated, initial investigations are promising. This chapter will explore our current knowledge of novel predictive biomarkers and discuss how they may be integrated into routine clinical use.
38#
發(fā)表于 2025-3-28 06:02:32 | 只看該作者
First-Line Systemic Treatment Options for Advanced Renal Cell Carcinomaapproved ICI combinations: ipilimumab/nivolumab, axitinib/pembrolizumab, axitinib/avelumab, cabozantinib/nivolumab, and lenvatinib/pembrolizumab. Challenges and approaches to therapeutic choices are also explored.
39#
發(fā)表于 2025-3-28 08:52:37 | 只看該作者
Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcition of SAbR with other local and systemic therapies is key in the optimal management of RCC patients. This chapter will discuss the rationale and available evidence for the integration and sequencing of SAbR with local and systemic therapies for RCC.
40#
發(fā)表于 2025-3-28 13:15:15 | 只看該作者
Radical Nephrectomy for Renal Cell Carcinomanefit. Management of RCC utilizing RN requires careful consideration of tumor size, location, local anatomy, and potential complication to select the proper technique and approach. This chapter reviews and describes relevant techniques, approaches, indications, outcomes, and considerations.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-27 22:18
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
天长市| 康平县| 莒南县| 盐山县| 惠安县| 章丘市| 徐闻县| 延津县| 西藏| 鄂温| 沙洋县| 安达市| 宁强县| 宜城市| 安新县| 苍梧县| 通化市| 文化| 井冈山市| 五原县| 犍为县| 泰兴市| 凤山县| 福州市| 苍梧县| 安国市| 寻乌县| 敦煌市| 铁岭市| 郧西县| 镇远县| 新闻| 伊宁县| 阜宁县| 延津县| 潜江市| 鲁甸县| 绥德县| 葵青区| 铜山县| 宁都县|